NewScen Coast Bio-Pharmaceutical Co., Ltd announced a private placement of 5.40 million shares at a price of CNY 8 per share for the gross proceeds of CNY 43.20 million on September 9, 2022. The transaction includes participation from new investor, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited. The transaction was approved by Board of directors of the company.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Singapore S.E.
Equities
T14
CNE100000924
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2 USD | +1.52% | +0.50% | -3.38% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.38% | 3.04B | |
+37.37% | 6.02B | |
-15.69% | 4.49B | |
-12.46% | 3.06B | |
+0.47% | 2.61B | |
+36.06% | 1.81B | |
+0.84% | 1.66B | |
-10.60% | 1.63B | |
-12.03% | 1.55B | |
+36.40% | 1.41B |
- Stock Market
- Equities
- 600329 Stock
- T14 Stock
- News Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
- NewScen Coast Bio-Pharmaceutical Co., Ltd announced that it expects to receive CNY 43.2 million in funding from Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited